Phuturdex › Diseases › Thyroid gland disease
Drugs in development · updated 30 October 2026
Thyroid gland disease: drugs in development
As of 30 October 2026 there are 13 active clinical trials (recruiting or ongoing, phases I–III) on 14 drugs for thyroid gland disease. 7 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Desiccated thyroid extract | III | 1 | NCT07239674 |
| Linsitinib | II–III | 1 | NCT06112340 |
| KL590586 | I–II | 1 | NCT05265091 |
| TOUR006 - | II | 1 | NCT06088979 |
| BHV-1300 | I | 1 | NCT06980649 |
| ETHY-001 | I | 1 | NCT07885605 |
| KIN-2787 | I | 1 | NCT04913285 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| LevothyroxineLevothyroxin, Synthroid | II–III | 2 | NCT06345339 |
| SelpercatinibLOXO-292, Retevmo® | I–II | 2 | NCT03157128 |
| EverolimusRAD001, Everoliumus | II | 1 | NCT01141309 |
| LiothyronineTriostat®, Cytomel® | II | 1 | NCT04115514 |
| RepotrectinibAugtyro® | I–II | 1 | NCT03093116 |
| SorafenibNexavar®, Sorafenib Accord® | II | 1 | NCT01141309 |
| BinimetinibMEK162, Mektovi® | I | 1 | NCT04913285 |
Sorted by most advanced phase and number of active trials.
All 14 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Thyroid neoplasm 99 drugs
- Graves' ophthalmopathy 19 drugs
- Melanoma 352 drugs
- Papillary thyroid cancer 15 drugs
- Graves' disease 13 drugs
- Non-small-cell lung carcinoma 726 drugs
- Colorectal neoplasm 534 drugs
- Cholangiocarcinoma 136 drugs
- Neoplasm 671 drugs
- Anaplastic thyroid carcinoma 24 drugs
- Breast neoplasm 593 drugs
- Glioma 184 drugs
Broader categories
- Endocrine system disease 19 drugs
- Nerve tissue neoplasm 4 drugs
- Digestive System Diseases 36 drugs
- Glandular and epithelial neoplasm 12 drugs
- Colorectal neoplasm 534 drugs
- Genetic disease 33 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D013959 “Thyroid Diseases”.